FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898796282> ?p ?o ?g. }

• W2898796282 abstract "The present study aimed to explore the underlying mechanisms of bone morphogenetic protein 2 (BMP2) in alleviating intervertebral disc degeneration (IDD). A rat puncture IDD model was constructed, and the rats were randomly divided into six groups: Control; IDD (model); IDD+PBS [containing 1010 adeno‑associated virus serotype 2 (AAV)]; and IDD + AAV2‑BMP2 (106, 108 and 1010). IL‑1β was used to treat primary nucleus pulposus (NP) cells to mimic IDD in vitro. The effects of BMP2 in IDD were determined by magnetic resonance imaging (MRI), hematoxylin and eosin staining and Alcian Blue staining in vivo. The levels of collagen II, aggrecan, transcription factor SOX9 (SOX9) and matrix metalloproteinase 13 (MMP‑13) were examined using western blot analysis and reverse transcription quantitative polymerase chain reaction (RT‑qPCR) in NP tissues and cells. The expression of C‑telopeptide of type II collagen (CTX‑II) in the sera or cell supernatants was determined by ELISA. In addition, the levels of phosphorylation of phosphoinositide 3‑kinase (PI3K) and protein kinase B (Akt), and the levels of apoptosis‑associated proteins and apoptosis ratio of NP cells were also determined by western blot analysis and flow cytometry, respectively. LY29400, an inhibitor of PI3K, was used to additionally confirm the signal pathway mechanism of BMP2 treatment in IDD. BMP2 significantly extended the interval between discs and alleviated the fibrous ring rupture and the decrease in the levels of glycoproteins in IDD rats, as determined by MRI and histological staining. Additionally, BMP2 treatment significantly upregulated the levels of collagen II, aggrecan and SOX9, but downregulated the levels of MMP‑13 and CTX‑II in IDD rats and NP cells in a dose‑dependent manner. Concurrently, recombinant human (rh)BMP2 pretreatment also significantly decreased the apoptosis ratio of interleukin (IL)‑1β‑treated NP cells via downregulating the level of cleaved caspase‑3 and upregulating the level of uncleaved poly (adenosine 5'‑diphosphate‑ribose) polymerase. It was demonstrated that rhBMP2 also significantly decreased the inflammatory response in NP tissues and cells, based on levels of IL‑6, TNF‑α and IL‑10. In addition, rhBMP2 inhibited cell apoptosis via upregulating the phosphorylation levels of the PI3K/Akt signaling pathway, and LY29400 pretreatment inhibited the effects of BMP2 in IL‑1β treated NP cells. BMP2 alleviated IDD via the PI3K/Akt signaling pathway by inhibiting NP cell apoptosis and decreasing the levels of matrix proteins." @default.
• W2898796282 created "2018-11-09" @default.
• W2898796282 creator A5018775731 @default.
• W2898796282 creator A5047568776 @default.
• W2898796282 creator A5049991457 @default.
• W2898796282 creator A5065294840 @default.
• W2898796282 creator A5086232386 @default.
• W2898796282 date "2018-11-02" @default.
• W2898796282 modified "2023-10-18" @default.
• W2898796282 title "Bone morphogenetic protein 2 alleviated intervertebral disc degeneration through mediating the degradation of ECM and apoptosis of nucleus pulposus cells via the PI3K/Akt pathway" @default.
• W2898796282 cites W1579579425 @default.
• W2898796282 cites W1780587196 @default.
• W2898796282 cites W1968914391 @default.
• W2898796282 cites W1986580482 @default.
• W2898796282 cites W1992937066 @default.
• W2898796282 cites W2007938150 @default.
• W2898796282 cites W2009182854 @default.
• W2898796282 cites W2030844880 @default.
• W2898796282 cites W2040797882 @default.
• W2898796282 cites W2052886320 @default.
• W2898796282 cites W2059660194 @default.
• W2898796282 cites W2063142742 @default.
• W2898796282 cites W2070732456 @default.
• W2898796282 cites W2075593123 @default.
• W2898796282 cites W2081264270 @default.
• W2898796282 cites W2090581967 @default.
• W2898796282 cites W2107277218 @default.
• W2898796282 cites W2129070301 @default.
• W2898796282 cites W2140568669 @default.
• W2898796282 cites W2148128675 @default.
• W2898796282 cites W2166016039 @default.
• W2898796282 cites W2168989311 @default.
• W2898796282 cites W2202679409 @default.
• W2898796282 cites W2204993185 @default.
• W2898796282 cites W2283044168 @default.
• W2898796282 cites W2301920403 @default.
• W2898796282 cites W2323209002 @default.
• W2898796282 cites W2333921594 @default.
• W2898796282 cites W2504171339 @default.
• W2898796282 cites W2520935284 @default.
• W2898796282 cites W2525414772 @default.
• W2898796282 cites W2528148796 @default.
• W2898796282 cites W2576296968 @default.
• W2898796282 cites W2606193240 @default.
• W2898796282 cites W2616383137 @default.
• W2898796282 cites W2661488461 @default.
• W2898796282 cites W2724694137 @default.
• W2898796282 cites W2742585201 @default.
• W2898796282 cites W588555666 @default.
• W2898796282 doi "https://doi.org/10.3892/ijmm.2018.3972" @default.
• W2898796282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30387830" @default.
• W2898796282 hasPublicationYear "2018" @default.
• W2898796282 type Work @default.
• W2898796282 sameAs 2898796282 @default.
• W2898796282 citedByCount "23" @default.
• W2898796282 countsByYear W28987962822020 @default.
• W2898796282 countsByYear W28987962822021 @default.
• W2898796282 countsByYear W28987962822022 @default.
• W2898796282 countsByYear W28987962822023 @default.
• W2898796282 crossrefType "journal-article" @default.
• W2898796282 hasAuthorship W2898796282A5018775731 @default.
• W2898796282 hasAuthorship W2898796282A5047568776 @default.
• W2898796282 hasAuthorship W2898796282A5049991457 @default.
• W2898796282 hasAuthorship W2898796282A5065294840 @default.
• W2898796282 hasAuthorship W2898796282A5086232386 @default.
• W2898796282 hasBestOaLocation W28987962821 @default.
• W2898796282 hasConcept C104317684 @default.
• W2898796282 hasConcept C105702510 @default.
• W2898796282 hasConcept C125349252 @default.
• W2898796282 hasConcept C142724271 @default.
• W2898796282 hasConcept C153911025 @default.
• W2898796282 hasConcept C181628713 @default.
• W2898796282 hasConcept C185592680 @default.
• W2898796282 hasConcept C190283241 @default.
• W2898796282 hasConcept C197534660 @default.
• W2898796282 hasConcept C202751555 @default.
• W2898796282 hasConcept C204787440 @default.
• W2898796282 hasConcept C2776164576 @default.
• W2898796282 hasConcept C2776415932 @default.
• W2898796282 hasConcept C2780550940 @default.
• W2898796282 hasConcept C2781013607 @default.
• W2898796282 hasConcept C3020332539 @default.
• W2898796282 hasConcept C30352789 @default.
• W2898796282 hasConcept C31507581 @default.
• W2898796282 hasConcept C55493867 @default.
• W2898796282 hasConcept C71924100 @default.
• W2898796282 hasConcept C75217442 @default.
• W2898796282 hasConcept C86554907 @default.
• W2898796282 hasConcept C86803240 @default.
• W2898796282 hasConcept C95444343 @default.
• W2898796282 hasConceptScore W2898796282C104317684 @default.
• W2898796282 hasConceptScore W2898796282C105702510 @default.
• W2898796282 hasConceptScore W2898796282C125349252 @default.
• W2898796282 hasConceptScore W2898796282C142724271 @default.
• W2898796282 hasConceptScore W2898796282C153911025 @default.
• W2898796282 hasConceptScore W2898796282C181628713 @default.
• W2898796282 hasConceptScore W2898796282C185592680 @default.
• W2898796282 hasConceptScore W2898796282C190283241 @default.
• W2898796282 hasConceptScore W2898796282C197534660 @default.
• W2898796282 hasConceptScore W2898796282C202751555 @default.

• next